GlobeNewswire by notified

Bavarian Nordic Provides Update on the Phase 3 Program for its COVID-19 Booster Vaccine Candidate

Share
  • Phase 3 trial of ABNCoV2, a non-adjuvanted COVID-19 booster vaccine candidate, has been redesigned as comparator vaccine has now become available, enabling a double-blind, controlled study to demonstrate non-inferiority of ABNCoV2 to a licensed mRNA vaccine
  • The fully sponsored trial will be initiated in August 2022, overall timelines remain unaffected with data read out still anticipated late in 2022 and subsequent approval in 2023

COPENHAGEN, Denmark, June 16, 2022 – Bavarian Nordic A/S (OMX: BAVA) today provided an update on the Phase 3 development of ABNCoV2, a VLP-based, non-adjuvanted COVID-19 booster vaccine candidate.

The upcoming Phase 3 trial has been redesigned to include a licensed mRNA-based vaccine (Comirnaty®) in the comparator arm of the study, to potentially support the primary objective of the study and demonstrate that the neutralizing antibodies induced by ABNCoV2 are non-inferior to the levels stimulated by the licensed mRNA-based vaccine. The addition of the comparator vaccine for clinical trial use has now been made possible in cooperation with regulatory authorities and vaccine manufacturers, and enables Bavarian Nordic to conduct a double-blind, controlled Phase 3 trial.

The Phase 3 trial will enroll approximately 4,000 adult subjects who either previously completed primary vaccination or have already received one booster dose of a licensed COVID-19 vaccine. The trial consists of two groups, which will run in parallel. The active, controlled group will enroll 1,000 subjects who will be randomized to receive either a single 100 µg dose of ABNCoV2 or a single 30 µg adult booster dose of Comirnaty. The other group will evaluate the safety and tolerability of the vaccine in 3,000 subjects who will receive a single 100 µg dose of ABNCoV2.

Based on the new design, the Phase 3 trial will now start enrolling in August 2022, but the overall timelines for trial remain unaffected. Thus, the Company still anticipates the initial data read-out before the end of 2022, which will allow for a rolling submission to the regulatory authorities, aiming to obtain approval of the vaccine in 2023.

Paul Chaplin, President and CEO of Bavarian Nordic, commented: “We are pleased to be able to run the Phase 3 trial of ABNCoV2 as a double-blind, controlled study, which provides us with a more robust foundation for the regulatory process towards approval. With its differentiated approach, we believe that ABNCoV2 could provide several advantages over the current licensed COVID-19 vaccines and look forward to initiating the study and presenting the first Phase 3 data for this universal booster vaccine candidate later this year.”

About ABNCoV2
ABNCoV2 is a next-generation COVID-19 vaccine candidate, initially developed by AdaptVac, Denmark using their proprietary capsid virus like particle (cVLP) technology. Bavarian Nordic has licensed the global commercialization rights to the vaccine and has assumed the responsibility for further clinical development towards licensure.

ABNCoV2 has shown to be highly immunogenic in relevant preclinical models inducing a durable and highly protective response from a COVID-19 challenge. Results from a Phase 2 trial has confirmed the ability of ABNCoV2 to significantly boost antibody titers as previously demonstrated in preclinical and Phase 1 clinical trials, and also confirm the potential of ABNCoV2 to boost antibody titers against SARS-CoV2 variants of concern.
The Phase 3 development of ABNCoV2 is being funded through an agreement with the Danish State.

About Bavarian Nordic
Bavarian Nordic is a fully integrated vaccines company focused on the development, manufacturing and commercialization of life-saving vaccines. We are a global leader in smallpox vaccines and have been a long-term supplier to the U.S. Government of a non-replicating smallpox vaccine, which has been approved by the FDA, also for the protection against monkeypox. The vaccine is also approved for protection against smallpox and monkeypox in Canada, and as a smallpox vaccine in Europe. Our commercial product portfolio furthermore contains market-leading vaccines against rabies and tick-borne encephalitis. Using our live virus vaccine platform technology, MVA-BN®, we have created a diverse portfolio of proprietary and partnered product candidates designed to save and improve lives by unlocking the power of the immune system, including an Ebola vaccine, which is licensed to the Janssen Pharmaceutical Companies of Johnson & Johnson. We are also committed to the development of a next generation COVID-19 vaccine. For more information visit www.bavarian-nordic.com.

Forward-looking statements
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.

Contacts
Europe: Rolf Sass Sørensen, Vice President Investor Relations, Tel: +45 61 77 47 43
US: Graham Morrell, Paddock Circle Advisors, graham@paddockcircle.com, Tel: +1 781 686 9600

Press Release

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Cloudbeds Acquires Whistle, Moves to Solve Friction in Guest Journey27.6.2022 14:00:00 CEST | Press release

No. 1 PMS and No. 1 guest messaging platform join forces to integrate guest engagement solutions seamlessly into day-to-day lodging business operations SAN DIEGO, June 27, 2022 (GLOBE NEWSWIRE) -- Cloudbeds, the hospitality management platform powering more reservations and happier guests for lodging businesses around the globe, announced today at HITEC 2022 the acquisition of the industry’s leading guest engagement solution, Whistle. Together, the companies will integrate their best-in-class technologies to remove friction points in the guest journey through a single platform. “The term contactless is becoming far too synonymous with hospitality,” said Richard Castle, COO and Co-Founder of Cloudbeds. “We want more contact between lodging businesses and their guests to create purposeful touchpoints, answer questions and provide guidance through the entire guest journey. Research shows that engaged guests spend more, leave better reviews and the majority prefer to communicate via digita

Arcoma vinner viktig upphandling i Finland. (MAR)27.6.2022 13:00:00 CEST | Pressemelding

2022-06-27 PRESSRELEASE Arcoma vinner viktig upphandling i Finland. Arcoma AB har vunnit viktig upphandlingpå upp till 6Arcoma Precision i5-system till ”HUS Medical Imaging Center” i Finland.Tre av systemen kommer att installeras under 2022 och kontraktet har en option på ytterligare tre system för installation under 2023. Det totala ordervärdet är upp till cirka 7,5MSek, beroende på tillval och optioner. Upphandlingen är vunnen av Lifemed Medical Systems som är Arcomas distributör och samarbetspartner i Finland och slutkunden är ”HUS Medical Imaging Center” som är en del av Helsingfors universitetssjukhus. "Vi är mycket glada över denna möjlighet att leverera dessa system till HUS, tillsammans med vår partner Arcoma. Ergonomi, patientsäkerhet och bra bildkvalitet var nyckelfaktorerna i detta anbud och Precision i5 är en perfekt lösning för att möta dessa behov ”, säger Mikko Isoviita, Sales Manager Lifemed Medical Systems. "Det är mycket glädjande att vi genom Lifemed vunnit denna upp

Arcoma wins important procurement in Finland. (MAR)27.6.2022 13:00:00 CEST | Press release

2022-06-27 PRESSRELEASE Arcoma wins important procurement in Finland. Arcoma AB has won important procurement of up to 6 Arcoma Precision i5 systems to “HUS Medical Imaging Center” in Finland. Three of the systems will be installed in 2022 and the contract has an option for three more systems for installation in 2023. The total order value is up to approximately SEK 7.5 million, depending on options. The procurement was won by Lifemed Medical Systems, which is Arcoma's distributor and partner in Finland, and the end customer is the “HUS Medical Imaging Center”, which is part of Helsinki University Hospital. "We are very pleased for this opportunity to supply these systems to HUS, together with our long-term partner Arcoma. Ergonomics, patient safety and good image quality were they key factors in this tender and Precision i5 is a perfect solution to address these needs”, says Mikko Isoviita, Sales Manager Lifemed Medical Systems. "It is great that we through Lifemed have won this procu

Change in Aspo’s Group Executive Committee27.6.2022 10:20:00 CEST | Press release

Aspo Plc Stock exchange release June 27, 2022 at 11:20 a.m. Change in Aspo’s Group Executive Committee Heli Arantola, Managing Director of Aspo’s subsidiary Leipurin, has resigned to join another company. Arantola will leave the company in December at the latest, and the process of selecting her successor has begun. “I thank Heli for her excellent contribution to the modernization of Leipurin and transforming the company in the rapidly changing bakery and food industry. I wish her the best of luck in her future endeavors,” says Rolf Jansson, CEO of Aspo Group. Aspo Plc Rolf Jansson CEO Further information, please contact: Rolf Jansson, CEO, Aspo Plc, +358 400 600 264, rolf.jansson@aspo.com DISTRIBUTION: Nasdaq Helsinki Key media www.aspo.com Aspo creates value by owning and developing business operations sustainably and in the long term. Our companies aim to be market leaders in their sectors. They are responsible for their own operations, customer relationships and the development of

Cool Company Ltd. – Mandatory Notification Of Trade27.6.2022 10:17:48 CEST | Press release

EPS Ventures Ltd., close associate of Cyril Ducau, Chair of the Board of Cool Company Ltd. (the “Company”), has on 24 June 2022 acquired 7,035 shares in the Company at a price of NOK 89.307527 per share. Following the transaction, EPS Ventures Ltd. holds a total of 15,598,523 shares in the Company, equivalent to 38.99% of the Company’s shares. Please see attached notification form in accordance with the Market Abuse Regulation article 19. This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act Attachment Primary insider notification form